Asia MDS Patient Registry
Part of Blood & lymphatic clinical trials.
This study is a registry that collects information from people with MDS in Asia. It helps doctors learn more about the condition and how it is managed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were at least 18 years old when diagnosed with MDS.
- Your MDS diagnosis was made by a doctor using standard WHO criteria between January 2019 and December 2022, or between October 2025 and September 2026.
- Your MDS diagnosis happened within 100 days of a bone marrow biopsy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects information from people with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) that developed after cancer treatment. It does not test a new drug but helps doctors learn more about these conditions.
This study is building a national platform in Spain to better understand MDS (a bone marrow disorder) and to help tailor treatments to each person. By joining, you help researchers learn more about your condition and how to manage it.
This study is a registry that collects information from people newly diagnosed with myelodysplastic syndrome (MDS). It helps researchers understand the condition better and may guide future studies.
This study is a database that collects information from people diagnosed with myelodysplastic syndromes. It may help researchers better understand the condition and how patients do over time.
This study collects medical information and blood samples from people with myelodysplastic syndrome (a blood disorder affecting how bone marrow makes blood cells) or related conditions. The goal is to understand these diseases better and improve care.
This study carefully evaluates people with myelodysplastic syndromes (MDS) and closely related blood disorders using detailed medical, blood, and bone marrow testing. The goal is to better understand these conditions and how they progress, which may help guide future care.
Hear when a new Myelodysplastic Syndromes (MDS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.